Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Serum bile acid level and fatty acid composition in Chinese children with non-alcoholic fatty liver disease

(2017) Li Ping Lu et al.   Journal of Digestive Diseases

Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD

(2017) Valerio Nobili et al.   LIVER INTERNATIONAL

Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes

(2016) David P. Sonne et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma

(2015) Arndt Weinmann et al.   BMC CANCER

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

(2015) Daniel Jahn et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Short-term and Divergent Regulation of FGF-19 and FGF-21 during Oral Lipid Tolerance Test but not Oral Glucose Tolerance Test

(2015) A. Schmid et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

S2k-Leitlinie nicht alkoholische Fettlebererkrankungen

(2015) E. Roeb et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

(2015) Stephen L. Roesch et al.   PLoS One

Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients

(2014) J M Gallego-Escuredo et al.   INTERNATIONAL JOURNAL OF OBESITY

Übergewicht und Adipositas in Deutschland

(2013) G.B.M. Mensink et al.   Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz

Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels

(2013) Qichen Fang et al.   DIABETES CARE

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

(2013) Anna Alisi et al.   PLoS One

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

(2012) Fatih Eren et al.   CLINICAL BIOCHEMISTRY

Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis

(2011) Constantinos Mihas et al.   Current Vascular Pharmacology

Alterations of Hormonally Active Fibroblast Growth Factors after Roux-en-Y Gastric Bypass Surgery

(2011) Peter L.M. Jansen et al.   DIGESTIVE DISEASES

Human Fatty Liver Disease: Old Questions and New Insights

(2011) J. C. Cohen et al.   SCIENCE

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance

(2010) Tim C. M. A. Schreuder et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Epidemiology of Non-Alcoholic Fatty Liver Disease

(2010) Stefano Bellentani et al.   DIGESTIVE DISEASES

FGFs and metabolism

(2009) Alexei Kharitonenkov   CURRENT OPINION IN PHARMACOLOGY

Definition and natural history of metabolic steatosis: histology and cellular aspects

(2009) V. Paradis et al.   DIABETES & METABOLISM

The role of the lipogenic pathway in the development of hepatic steatosis

(2009) C. Postic et al.   DIABETES & METABOLISM

Bile acids: regulation of synthesis

(2009) John Y. L. Chiang   JOURNAL OF LIPID RESEARCH

The Klotho gene family as a regulator of endocrine fibroblast growth factors

(2008) Hiroshi Kurosu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Fibroblast growth factor‐19: Development, analytical characterization and clinical evaluation of a new ELISA test

(2008) D. Stejskal et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION